GlassScriptPhysician profile
Steven Douglas Shay
NPI 1629070222
$4,883.85
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,201 · 2020: $699 · 2021: $1,030 · 2022: $1,002 · 2023: $952.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $939 · Education: $13.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $938.78 |
| Education | $13.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $925.40 | 2019-2023 | Farxiga, Breztri, Saphnelo |
| Novo Nordisk INC | $791.34 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $540.99 | 2019-2023 | Trelegy Ellipta, Shingrix, Bexsero |
| Lilly USA, LLC | $463.54 | 2019-2023 | Jardiance, Mounjaro, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $388.94 | 2019-2023 | Tradjenta, Jardiance, Synjardy |
| Abbvie INC. | $336.88 | 2021-2023 | Ubrelvy, Qulipta |
| Pfizer INC. | $274.61 | 2019-2023 | |
| Amgen INC. | $192.13 | 2019-2023 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $167.58 | 2019-2023 | Gardasil 9, Vaxneuvance, Proquad |
| Sanofi-Aventis U.S. LLC | $158.34 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $102.98 | 2019-2021 | |
| Sanofi Pasteur INC. | $93.82 | 2019-2023 | |
| Abbott Laboratories | $83.32 | 2021-2023 | Freestyle Libre 3 |
| Braintree Laboratories, INC. | $61.16 | 2019 | |
| Seqirus USA INC | $58.94 | 2022-2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $57.01 | 2019-2020 | |
| Exact Sciences Corporation | $44.46 | 2023 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $40.11 | 2022 | |
| Amarin Pharma, INC. | $30.25 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $27.30 | 2020-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.70 | 2023 | |
| Janssen Pharmaceuticals, INC | $12.72 | 2019 | |
| Astellas Pharma US INC | $12.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Shay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.